Search PubMed⌕ Search

Biomedical subjects

E Molina

Publications and source records attributed to E Molina.

At least 145 records · Page 8Linked to original sources
PubMed1976

Measurement of DNA antibodies.

Modifications of the standard Farr technic for assaying DNA antibodies are presented; these result in improved separation of normals from abnormals, enhanced reproducibility, and simplicity of performance. The use of 0.4 M borate buffer extends the range of the assay, while a 0.1 M buffer aids differentiation when equivocal results are obtained. Centrifugation of vials prior to counting improves the reproducibility by approximately 3%. Polyethylene glycol, at a final concentration of 6 Gm. per 100 ml., can be substituted for ammonium sulfate, with some advantages.

Antibodies↗
PubMed1976

Nucleoprotein-coated latex particles in the serologic diagnosis of systemic lupus erythematosus. A comparative clinical and serologic study.

A commercially available test for systemic lupus erythematosus employing nucleoprotein-coated latex particles has been evaluated both clinically and serologically. The sera from all 40 subjects with active SLE had positive latex tests, while all 28 sera from healthy adults had negative latex tests. False-positive latex tests were observed in five of 13 antinuclear factor-positive patients with other chronic inflammatory diseases. Specific DNAase and RNAase digestion of the latex particles suggested the false-positive results were due to DNA moieties, other than native DNA, coating the latex particles.

Antibodies↗
PubMed1976

[Effects of various natural prostaglandins on human gastrointestinal motility in vitro].

The effects of three natural prostaglandins, E1, E2 and F2alpha, on the human gastrointestinal tract were investigated by means of an in vitro technique. Prostaglandin F2alpha showed a stimulatory effect on all the segments examined and its activity was comparable to that of acetylcholine (threshold doses 0.5-2 mug). Prostaglandin E1 relaxed the circular muscles of the stomach (minimum active dose was 1 mug/ml) but contracted the longitudinal ones and taenia coli. Prostaglandin E2 showed an interesting inhibition of the stimulant effect of acetylchooline on circular muscles of the stomach (1 mug/ml) and a weak spasmogenic activity on the other tracts. The mechanism of action of prostaglandins has not been completely elucidated; it seems plausible to suggest a direct effect of the drugs on the smooth muscle, however the release of an unknown mediator cannot be excluded.

Gastrointestinal Motility↗
PubMed1975

[Spasmolytic effect of mebeverine on the gastrointestinal motility].

Mebeverine, N-ethyl-4'-[1-methyl-2-(4-methoxyphenyl)ethylamino] butyl-3,4-dimetoxybenzoate, was studied for its inhibitory effect on the motility of the gastrointestinal tract in vivo and in vitro. In both cases its activity was more evident on the hypermotility induced by some common physiological spasmogenic agents than on basal motility. In various tests it was ascertained that mebeverine was able to inhibit the stimulant actions of all the drugs employed, both those acting on specific receptor sites such as histamine and acetylcholine, and those acting directly on the smooth muscle such as substance P, physalaemin etc. This backs up the suggestion of a nonspecific miotropic effect of mebeverine. This compound has the same spasmolytic action at different levels of the gastrointestinal tract and is decisively stronger than papaverine. The lack of remarkable side-effects in the tests which were carried out in vivo with decisively active doses on the gastrointestinal motility and the good inhibitory effect on human isolated strips of the gastrointestinal tract suggest that mebeverine may be useful in the treatment of clinical morbid conditions characterized by hypertone or hypermotility of the gastrointestinal tract.

Animals↗
PubMedDate not supplied

Somatostatin, prostaglandin E2 and atropine inhibition of the gastric actions of bombesin in the dog.

Bombesin, acetylcholine, prostaglandins and somatostatin are all thought to be involved in the regulation of gastrin release and gastric secretion. We have studied the effects of low doses of atropine, 16-16(Me)2-prostaglandin E2 (PGE2) and somatostatin-14 on bombesin-stimulated gastrin release and gastric acid and pepsin secretion in conscious fistula dogs. For reference, synthetic gastrin G-17 was studied with and without somatostatin. Bombesin, in a dose-related manner, increased serum gastrin, which in turn stimulated gastric acid and pepsin secretion in a serum gastrin, concentration-dependent manner. Somatostatin inhibited gastrin release by bombesin as well as the secretory stimulation by G-17; the combination of sequential effects resulted in a marked inhibition of bombesin-stimulated gastric acid and pepsin secretion. PGE2 also strongly inhibited gastrin release and acid and pepsin secretion. Atropine had no significant effect on gastrin release, but greatly inhibited gastric secretion. Thus somatostatin and PGE2 inhibited at two sites, gastrin release and gastrin effects, while atropine affected only the latter.

Animals↗